By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



P.O. Box 12878

Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-544-8600 Fax: 919-544-8697




Merck & Co.  Antifungals

Company News
SCYNEXIS, Inc. (SCYX) Completes Two Additional Clinical Studies Further Supporting The Favorable Safety Profile Of SCY-078 10/25/2016 8:05:10 AM
Why SCYNEXIS, Inc. (SCYX) Is Making A Run 10/7/2016 7:33:22 AM
SCYNEXIS, Inc. (SCYX) Announces Complete Results From Two Phase II Studies Of Oral SCY-078 In Patients With Candida Spp. Infections And Closing Of A $15 Million Term Loan 10/6/2016 7:16:02 AM
SCYNEXIS, Inc. (SCYX) To Present At The Ladenburg Thalmann Healthcare Conference 9/20/2016 8:10:55 AM
SCYNEXIS, Inc. (SCYX) To Present At Upcoming Investor Conferences 8/31/2016 7:56:58 AM
SCYNEXIS, Inc. (SCYX) Receives Orphan Drug Designation For SCY-078 For The Treatment Of Invasive Aspergillus Infections 8/25/2016 8:06:52 AM
SCYNEXIS, Inc. (SCYX) Reports Second Quarter 2016 Financial Results And Provides Company Update 8/8/2016 8:20:21 AM
SCYNEXIS, Inc. (SCYX) To Present At The Canaccord Genuity Growth Conference 8/4/2016 8:30:27 AM
SCYNEXIS, Inc. (SCYX) Announces Interim Results From Phase II Study Of Oral SCY-078 In Patients With Invasive Candidiasis 8/1/2016 10:52:10 AM
SCYNEXIS, Inc. (SCYX) Announces Sale Of Cyclophilin Inhibitor Assets To Cypralis Limited 7/13/2016 8:12:34 AM